MX354649B - Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. - Google Patents

Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos.

Info

Publication number
MX354649B
MX354649B MX2011008331A MX2011008331A MX354649B MX 354649 B MX354649 B MX 354649B MX 2011008331 A MX2011008331 A MX 2011008331A MX 2011008331 A MX2011008331 A MX 2011008331A MX 354649 B MX354649 B MX 354649B
Authority
MX
Mexico
Prior art keywords
pharmaceutical
organic compounds
grade ferric
ferric organic
methods
Prior art date
Application number
MX2011008331A
Other languages
English (en)
Inventor
Winston Town
Keith Chan
Original Assignee
Panion & Bf Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354649(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/206,981 external-priority patent/US7767851B2/en
Application filed by Panion & Bf Biotech Inc filed Critical Panion & Bf Biotech Inc
Publication of MX354649B publication Critical patent/MX354649B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe compuestos férricos orgánicos grado farmacéutico, que incluyen citrato férrico, los cuales son solubles sobre una escala de pH más amplia, y los cuales tienen una gran área de superficie activa; también se describe un procedimiento de control de calidad y fabricación para elaborar un citrato férrico grado farmacéutico que cumpla de manera consistente con la Especificación de Liberación de Fabricación; los compuestos férricos orgánicos grado farmacéutico son adecuados para tratar trastornos caracterizados por niveles elevados de fosfato en suero.
MX2011008331A 2005-08-18 2006-08-18 Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. MX354649B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/206,981 US7767851B2 (en) 2003-02-19 2005-08-18 Ferric organic compounds, uses thereof and methods of making same
US70951105P 2005-08-19 2005-08-19
PCT/US2006/032385 WO2007022435A2 (en) 2005-08-18 2006-08-18 Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same

Publications (1)

Publication Number Publication Date
MX354649B true MX354649B (es) 2018-03-14

Family

ID=48087784

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008002360A MX2008002360A (es) 2005-08-18 2006-08-18 Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos.
MX2011008331A MX354649B (es) 2005-08-18 2006-08-18 Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008002360A MX2008002360A (es) 2005-08-18 2006-08-18 Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos.

Country Status (16)

Country Link
EP (2) EP1931689B1 (es)
JP (2) JP5667343B2 (es)
KR (1) KR20080037083A (es)
CN (1) CN101253186A (es)
AU (1) AU2006279333C1 (es)
CA (2) CA2619591C (es)
DK (1) DK1931689T3 (es)
EA (1) EA018245B1 (es)
ES (1) ES2539635T3 (es)
HU (1) HUE025264T2 (es)
IL (2) IL189583A (es)
MX (2) MX2008002360A (es)
MY (1) MY162727A (es)
NZ (1) NZ566743A (es)
TW (1) TWI375555B (es)
WO (1) WO2007022435A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
WO2007089571A2 (en) * 2006-01-30 2007-08-09 Globoasia, Llc Method of treating chronic kidney disease
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
WO2008058438A1 (fr) * 2006-11-17 2008-05-22 Jung-Ren Su Utilisation de citrate ferrique dans la préparation de médicaments servant à traiter la calcification des vaisseaux sanguins
WO2009032538A1 (en) * 2007-08-31 2009-03-12 C.B. Fleet Company, Inc. Method of preventing nephrocalcinosis
CN102573807A (zh) 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型
JP5167389B2 (ja) * 2010-07-07 2013-03-21 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤
US20120238622A1 (en) * 2011-01-18 2012-09-20 Japan Tobacco Inc. Iron (iii) citrate, substantially free of beta-iron hydroxide oxide
KR101455921B1 (ko) * 2012-01-30 2014-11-12 성균관대학교산학협력단 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법
KR102150135B1 (ko) 2012-06-21 2020-08-31 케릭스 바이오파마슈티컬스 인코포레이티드 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
EP3653061A1 (en) * 2012-09-04 2020-05-20 The Board of Regents of the University of Texas System Citrate-rich calcium-magnesium supplement and uses thereof
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
EP3747432A1 (en) * 2013-11-04 2020-12-09 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
ES2857177T3 (es) 2014-12-10 2021-09-28 Tricida Inc Polímeros de unión de protones para administración oral
CN107108443A (zh) * 2014-12-17 2017-08-29 拜欧弗印度制药有限公司 合成铁有机化合物的改进方法
JP6206420B2 (ja) * 2015-01-13 2017-10-04 テクノサイエンス株式会社 クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法
EP3265077A4 (en) * 2015-03-04 2018-10-24 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
US20190209607A1 (en) 2016-05-06 2019-07-11 Tricida, Inc. Compositions for treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN108863771A (zh) * 2018-05-24 2018-11-23 国药集团化学试剂有限公司 一种柠檬酸铁结晶的制备方法
JP7175235B2 (ja) * 2019-04-19 2022-11-18 株式会社トクヤマ クエン酸第二鉄水和物の製造方法
CN110105194A (zh) * 2019-05-10 2019-08-09 上海万巷制药有限公司 一种药用级柠檬酸铁的制备方法
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
CN1315174A (zh) 2000-03-31 2001-10-03 苏荣仁 治疗肾衰的药物组合物
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate

Also Published As

Publication number Publication date
AU2006279333C1 (en) 2012-12-13
IL189583A (en) 2013-10-31
MY162727A (en) 2017-07-14
WO2007022435A2 (en) 2007-02-22
MX2008002360A (es) 2008-04-29
ES2539635T3 (es) 2015-07-02
EP1931689A2 (en) 2008-06-18
EA200800593A1 (ru) 2008-10-30
EA018245B1 (ru) 2013-06-28
CA3050453C (en) 2021-07-27
DK1931689T3 (en) 2015-06-01
TWI375555B (en) 2012-11-01
CA3050453A1 (en) 2007-02-22
EP1931689B1 (en) 2015-02-25
CN101253186A (zh) 2008-08-27
WO2007022435A3 (en) 2007-05-10
JP5667343B2 (ja) 2015-02-12
TW200740431A (en) 2007-11-01
AU2006279333B2 (en) 2012-07-26
AU2006279333A1 (en) 2007-02-22
IL228952B (en) 2018-06-28
EP2594551A1 (en) 2013-05-22
HUE025264T2 (en) 2016-02-29
JP2013177416A (ja) 2013-09-09
CA2619591A1 (en) 2007-02-22
IL189583A0 (en) 2008-08-07
JP2009504777A (ja) 2009-02-05
IL228952A0 (en) 2013-12-31
EP1931689A4 (en) 2011-02-09
CA2619591C (en) 2020-03-24
NZ566743A (en) 2010-07-30
KR20080037083A (ko) 2008-04-29

Similar Documents

Publication Publication Date Title
MY162727A (en) Pharmaceutical-grade ferric organic compounds, uses thereof, and methods of making the same
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2006113432A3 (en) Compounds, compositions and methods
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
ATE533497T1 (de) Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
WO2006102283A3 (en) Beta-lactamylalkanoic acids for treating premenstrual disorders
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
TW200621748A (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
WO2007089548A3 (en) Compounds and methods for modulating protein trafficking
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2008063287A3 (en) Novel imidazothiazoles and imidazoxazoles
WO2009011850A3 (en) Novel therapeutic compounds
TW200734311A (en) New compounds
WO2007022470A3 (en) Methods and compositions for treating neurological disease
IL188330A (en) Processes for the preparation of 4-amino-2- (6,2-dioxofipridine-3-il) compounds isoindoline-1,3-dion
WO2007028073A3 (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2006117660A3 (en) Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
DE602006016760D1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
WO2007089571A8 (en) Method of treating chronic kidney disease
WO2008036540A3 (en) Rho kinase inhibitors
CN104059013B8 (zh) 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
WO2007011760A3 (en) Inhibitors of mitotic kinesin
WO2005076861A3 (en) Compounds that inhibit hiv particle formation
WO2006000547A3 (de) Verfahren zur herstellung eines phosphatadsorbens auf eisensulfat-basis